Valuation, from the filing
| Public float | $807.89B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $856.40 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 39.1× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 12.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 30.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
Valuation over time
39.1× earnings today, against a median of 34.7× across 9 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-30 | $807.89B | 39.1× | |
| 2024-06-30 | $769.79B | 72.7× | |
| 2023-06-30 | $398.29B | 76.0× | |
| 2022-06-30 | $274.34B | 43.9× | |
| 2021-06-30 | $193.65B | 34.7× | |
| 2020-06-30 | $138.91B | 22.4× | |
| 2019-06-30 | $93.17B | 11.2× | |
| 2018-06-30 | $78.20B | 24.2× | |
| 2016-06-30 | $76.78B | 28.0× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| SBC / revenue | 1.0% | 4th | |
| Net margin | 31.7% | 92th | |
| Long-term debt / equity | 1.54x | 90th | |
| Current ratio | 1.58x | 23th | |
| Revenue YoY growth | 44.7% | 74th | |
| Gross margin | 83.0% | 71th | |
| Effective tax rate | 19.8% | 58th |
ELI LILLY & Co (LLY) reported revenue of $86.46B and net income of $27.58B for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ELI LILLY & Co’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-09-30 |
|---|---|
| Revenue | $86.46B |
| Cost of revenue | $14.15B |
| Gross profit | $72.31B |
| Operating income | Unavailable |
| Net income | $27.58B |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $34.77B |
| Income tax expense | $7.19B |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $12.62B |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-09-30 |
|---|---|
| Cash & equivalents | $4.88B |
| Total assets | $148.07B |
| Current assets | $65.26B |
| Total liabilities | Unavailable |
| Current liabilities | $47.00B |
| Total equity incl. NCI | $40.27B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $18.19B |
| Accounts receivable | $22.09B |
| Goodwill | $9.87B |
| Long-term debt | $46.99B |
| Accounts payable | $5.79B |
Cash flow
| Metric | 2026-09-30 |
|---|---|
| Operating cash flow | $30.64B |
| Capital expenditures | Unavailable |
| Investing cash flow | -$30.41B |
| Financing cash flow | -$5.14B |
| Net change in cash | -$4.91B |
| Stock-based compensation | $698.00M |
| Common dividends paid | $5.98B |
| Common share repurchases | $5.84B |
| Depreciation & amortization | $2.17B |
Derived
| Metric | 2026-09-30 |
|---|---|
| Free cash flow | Unavailable |
| Gross margin | 83.6% |
| Operating margin | Unavailable |
| FCF margin | Unavailable |
| SBC / revenue | 0.8% |
| Current ratio | 1.39x |
| Revenue YoY growth | 45.5% |
| Net margin | 31.9% |
| R&D / revenue | Unavailable |
| CapEx / revenue | Unavailable |
| Long-term debt / equity | 1.17x |
| Effective tax rate | 20.7% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LLY in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.